<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1010350</article-id><article-id pub-id-type="publisher-id">ACM-38186</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201000000_54692136.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  自噬在食管鳞癌中的研究进展
  Research Progress of Autophagy in Esophageal Squamous Cell Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>云龙</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>振波</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>滨州医学院附属医院肿瘤科，山东 滨州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>10</day><month>10</month><year>2020</year></pub-date><volume>10</volume><issue>10</issue><fpage>2323</fpage><lpage>2328</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    自噬属于细胞程序性死亡，通过降解入侵的病原体、清除受损的细胞器及多余的脂质，降解的物质重新被机体利用以维持细胞稳态和器官完整性的作用。随着对自噬研究的逐渐深入，发现其与食管鳞癌的发生、发展密切相关，不仅在肿瘤的发生前期起着抑制作用，而且在食管鳞癌的发展中起到了促进作用。近年来发现在食管鳞癌的治疗中，通过对自噬的干预有着明显的效果。本文主要综述了细胞自噬的过程和机制、在食管鳞癌中的作用以及参与食管鳞癌治疗的研究进展。
    Autophagy is a kind of programmed cell death. By degrading invading pathogens, removing damaged organelles and excess lipids, the degraded substances are reused by the body to maintain cell homeostasis and organ integrity. With the deepening of the study on autophagy, it is found that it is closely related to the occurrence and development of esophageal squamous cell carcinoma, which not only plays an inhibitory role in the early stage of the occurrence of tumors, but also plays a promoting role in the development of esophageal cancer. In recent years, it has been found that the intervention of autophagy has obvious effects on the treatment of esophageal cancer. This paper mainly reviews the process and mechanism of autophagy, its role in esophageal cancer and autophagy’s involvement in the treatment of esophageal cancer. 
  
 
</p></abstract><kwd-group><kwd>自噬，食管鳞癌治疗，肿瘤免疫, Autophagy</kwd><kwd> Treatment of Esophageal Squamous Cell Carcinoma</kwd><kwd> Tumor Immunity</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>自噬属于细胞程序性死亡，通过降解入侵的病原体、清除受损的细胞器及多余的脂质，降解的物质重新被机体利用以维持细胞稳态和器官完整性的作用。随着对自噬研究的逐渐深入，发现其与食管鳞癌的发生、发展密切相关，不仅在肿瘤的发生前期起着抑制作用，而且在食管鳞癌的发展中起到了促进作用。近年来发现在食管鳞癌的治疗中，通过对自噬的干预有着明显的效果。本文主要综述了细胞自噬的过程和机制、在食管鳞癌中的作用以及参与食管鳞癌治疗的研究进展。</p></sec><sec id="s2"><title>关键词</title><p>自噬，食管鳞癌治疗，肿瘤免疫</p></sec><sec id="s3"><title>Research Progress of Autophagy in Esophageal Squamous Cell Carcinoma</title><p>Yunlong Zhang, Zhenbo Wang<sup>*</sup></p><p>Department of Oncology, Binzhou Medical University Hospital, Binzhou Shandong</p><p><img src="//html.hanspub.org/file/17-1571615x4_hanspub.png" /></p><p>Received: Sep. 30<sup>th</sup>, 2020; accepted: Oct. 18<sup>th</sup>, 2020; published: Oct. 22<sup>nd</sup>, 2020</p><p><img src="//html.hanspub.org/file/17-1571615x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Autophagy is a kind of programmed cell death. By degrading invading pathogens, removing damaged organelles and excess lipids, the degraded substances are reused by the body to maintain cell homeostasis and organ integrity. With the deepening of the study on autophagy, it is found that it is closely related to the occurrence and development of esophageal squamous cell carcinoma, which not only plays an inhibitory role in the early stage of the occurrence of tumors, but also plays a promoting role in the development of esophageal cancer. In recent years, it has been found that the intervention of autophagy has obvious effects on the treatment of esophageal cancer. This paper mainly reviews the process and mechanism of autophagy, its role in esophageal cancer and autophagy’s involvement in the treatment of esophageal cancer.</p><p>Keywords:Autophagy, Treatment of Esophageal Squamous Cell Carcinoma, Tumor Immunity</p><disp-formula id="hanspub.38186-formula6"><graphic xlink:href="//html.hanspub.org/file/17-1571615x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/17-1571615x8_hanspub.png" /> <img src="//html.hanspub.org/file/17-1571615x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>近几年食管鳞癌发病率有所下降，但死亡率一直位居第四位。据报道全世界新发患者数约45万例，而同年死亡人数约40万，其中发病和死亡人数我国约占1/2 [<xref ref-type="bibr" rid="hanspub.38186-ref1">1</xref>]。因此，明确食管鳞癌发生、发展的分子机制和途径，寻找更为有效的治疗方法和相关药物对于减少疾病发生率和死亡率有着重要意义。自噬在食管鳞癌中的功能作用复杂，具体机制和关系需要进一步研究。本文综述自噬相关效应因子在食管鳞癌中的临床意义，以及目前关于自噬参与食管鳞癌相关分子机制，探讨自噬抑制剂作为一种新的治疗手段，为食管鳞癌的治疗提供一种新的思路。</p><p>细胞自噬是程序性细胞死亡的一种，其本质是通过降解细胞质成分和入侵的病原体，降解所产生的物质被机体重新利用以调节稳态的过程 [<xref ref-type="bibr" rid="hanspub.38186-ref2">2</xref>]。相关研究表明，自噬与多种疾病相关，尤其在肿瘤中起到了双向调控的作用，在肿瘤发生早期对其有抑制作用，而在肿瘤进展中起到保护肿瘤的作用，这与肿瘤的类型、发展时期以及遗传因素等相关 [<xref ref-type="bibr" rid="hanspub.38186-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38186-ref4">4</xref>]。</p></sec><sec id="s6"><title>2. 自噬发生过程</title><p>自噬是一种在真核生物中保守的细胞内降解系统。主要过程分为四个阶段：自噬的诱导、激活；自噬体的成核及延伸；自噬体与溶酶体的结合；自噬溶酶体中内容物的降解 [<xref ref-type="bibr" rid="hanspub.38186-ref5">5</xref>]。自噬的标志是自噬体双膜结构的产生。例如自噬被饥饿诱导时，一个被称为隔离膜的膜囊出现并扩展成自噬小体。在这一过程中，包括蛋白质和细胞器在内的一部分细胞质局限在自噬体的腔内，自噬体和溶酶体融合后内部内容物被溶酶体水解酶降解 [<xref ref-type="bibr" rid="hanspub.38186-ref6">6</xref>]。根据运送到溶酶体或液泡的途径，自噬可分为三种主要类型：伴侣诱导的自噬、微自噬和巨自噬 [<xref ref-type="bibr" rid="hanspub.38186-ref7">7</xref>]。本研究主要讨论最为广泛研究的巨自噬，以下称之为自噬。哺乳动物中自噬体的形成机制暂不明确，而在酵母中这一途径是明确的。目前在酵母中已经发现了35个ATG基因 [<xref ref-type="bibr" rid="hanspub.38186-ref8">8</xref>]。雷帕霉素激酶(mechanistic target of rapamycin, mTOR)靶点作为各种应激反应的分子传感器，包括缺氧、胰岛素信号、能量和营养消耗，在细胞生长和自噬控制中发挥关键作用 [<xref ref-type="bibr" rid="hanspub.38186-ref9">9</xref>]。Atg13是Atg1激酶复合物上游自噬的重要调控成分，TORC1 (Tor complex1)在多个残基上直接磷酸化Atg13。此外，不能磷酸化的Atg13突变体的表达绕过了TORC1通路，通过激活Atg1 (哺乳动物中ULK1的同源基因)在营养丰富的条件下生长的细胞中诱导自噬 [<xref ref-type="bibr" rid="hanspub.38186-ref10">10</xref>]。Kamada 等人发现TORC1直接控制Atg1复合物可诱导自噬 [<xref ref-type="bibr" rid="hanspub.38186-ref11">11</xref>]。Atg1/Ulk1与Atg13和Atg17相互作用，调节跨膜蛋白Atg9，参与从细胞器中导入脂质，作为吞噬团形成的启动剂 [<xref ref-type="bibr" rid="hanspub.38186-ref12">12</xref>]。当III类PI3激酶，例如Vps34，与Beclin1 (哺乳动物酵母的同源物Atg6)结合，增强其催化活性以产生PI3P (磷脂酰肌醇-3-磷酸)时，噬菌体被拉长 [<xref ref-type="bibr" rid="hanspub.38186-ref13">13</xref>]。随着目标的吞噬，随后自噬体与溶酶体结合并融合形成称为自噬溶酶体的结构，其中酸性溶酶体成分消化所有货物。自噬体沿着微管双向迁移，在动力蛋白运动蛋白的作用下，自噬体自然倾向于富含溶酶体的微管组织中心，自噬溶酶体形成后将其中将所吞噬物分解成氨基和脂肪酸运输回细胞质池 [<xref ref-type="bibr" rid="hanspub.38186-ref14">14</xref>]。</p></sec><sec id="s7"><title>3. 自噬在食管鳞癌进展中是一把双刃剑</title><p>近年来，自噬在肿瘤中的作用已得到较为广泛的研究，同时自噬相关蛋白的生物学效应机制被深入地探讨。肿瘤的发生发展存在复杂性和不确定性，因此不能用单一的机制来概括自噬与癌症的关系。一方面自噬可能通过以下途径发挥抑制肿瘤的功能：(1) 限制染色体不稳定性，从而防止致癌突变的积累；(2)抑制氧化应激，氧化应激也是一种致癌刺激，可以减少瘤内坏死和局部炎症；另一方面，自噬的增强是肿瘤细胞逃避缺氧、代谢、分离诱导和治疗应激的重要机制 [<xref ref-type="bibr" rid="hanspub.38186-ref15">15</xref>]。研究表明自噬的激活可以促进食管鳞癌细胞存活与转移并且增加化疗耐药性，从而对食管鳞癌的进展具有促进作用。</p><sec id="s7_1"><title>3.1. 自噬相关基因抑制食管鳞癌的发生与进展</title><p>Beclin-1基因主导控制着细胞的自噬行为，直接参与自噬小体的形成，也是自噬活化的关键，体外试验明激活Beclin-1活化自噬可以抑制肿瘤的发生 [<xref ref-type="bibr" rid="hanspub.38186-ref16">16</xref>]。相关研究发现，食管鳞癌组织中Beclin-1基因的表达明显低于邻近的正常食管组织，且分化程度较低的肿瘤，Beclin-1基因表达水平较低。淋巴结转移也表现出同样的特点 [<xref ref-type="bibr" rid="hanspub.38186-ref17">17</xref>]。组织坏死能够激活炎症反应从而促进肿瘤的增殖，而自噬却可以阻止坏死的发生，以此抑制肿瘤的发生。Degenhardt等提出Beclin-1的缺失，会导致抗凋亡蛋白Bcl-2的表达大量增加，进而促进肿瘤发生。Mathew发现敲除Beclin-1的小鼠更容易发生肿瘤，恰恰证明了此类观点 [<xref ref-type="bibr" rid="hanspub.38186-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.38186-ref19">19</xref>]。也有学者发现，Bcl-2 (被证明能与Beclin-1相互作用)家族的癌蛋白和肿瘤抑制蛋白也控制自噬，这一事实进一步证实了自噬抑制可能有利于肿瘤的发展。这从侧面证实了自噬抑制肿瘤的作用 [<xref ref-type="bibr" rid="hanspub.38186-ref20">20</xref>]。miR-503通过蛋白激酶A (PKA)哺乳动物雷帕霉素靶点(mTOR)途径在ESCC细胞中触发自噬，进一步通过细胞试验发现自噬的增强抑制食管鳞癌细胞的增殖和转移。此外，多种抑癌基因通过调节自噬进而发挥抑制肿瘤的作用 [<xref ref-type="bibr" rid="hanspub.38186-ref21">21</xref>]。例如：TSC1和TSC2 [<xref ref-type="bibr" rid="hanspub.38186-ref22">22</xref>] 可以作为 mTOR信号通路上游的抑制因子，可以直接激活自噬的发生。这些观察结果有力地支持了自噬抑制有利于肿瘤发生的观点，进而表明自噬可能是一种真正的肿瘤抑制机制。可以提出三个假设来解释自噬减少如何刺激肿瘤发生。首先，据报道，自噬抑制增强了肿瘤内坏死细胞的死亡，因此可能通过加重局部炎症促进肿瘤生长。其次，研究表明，受损的自噬会促进染色体不稳定，特别是在受到代谢应激的细胞中，这可能导致癌基因激活和肿瘤进展。第三，缺陷自噬可能通过允许老化或受损细胞器的积累而促进肿瘤发生，而这些细胞器又可能作为固有基因毒性/致瘤性化学物质的来源。关于自噬抑制肿瘤的具体机制扔不明确，这也反映了未来研究的方向。</p></sec><sec id="s7_2"><title>3.2. 自噬对于食管鳞癌的进展及转移的促进作用</title><p>尽管自噬在肿瘤发生早期有着抑制炎症及坏死发生进而起到肿瘤的抑制作用，但当肿瘤进展到一定程度时自噬对于肿瘤细胞就有了保护作用。相关研究表明，随着肿瘤的进展自噬逐渐增强，并且为肿瘤细胞提供能量，加速其进展，另一方面自噬还会诱导黏附因子的改变，进而促进肿瘤细胞的侵袭和迁移 [<xref ref-type="bibr" rid="hanspub.38186-ref23">23</xref>]。多种细胞因子通过促进细胞自噬进而促进肿瘤细胞的生长。Wu等人对食管鳞癌患者的病理切片分析发现，CLDN1 (一种膜蛋白，是细胞黏附中紧密连接链的组成部分)与自噬的相关性，在随后的体内及体外实验中发现，CLDN1在食管鳞癌细胞中通过AMP活化蛋白激酶(AMPK)/信号转换器和转录激活剂1 (STAT1)信号通路增加ULK1的表达，从而诱导自噬，促进了食管鳞癌的增殖和转移 [<xref ref-type="bibr" rid="hanspub.38186-ref24">24</xref>]。目前自噬抑制剂的应用有效抑制肿瘤的增殖，这也从侧面说明自噬在食管鳞癌的进展中起到了促进作用。Feng等人通过选择5-氟尿嘧啶(5-FU)作为化疗药物，LY294002作为自噬抑制剂，应用于体外培养的食管鳞癌细胞株，发现二者联合应用具有更高的细胞毒作用，在癌细胞中表现出明显更高的抗癌效果。自噬抑制剂的应用，提高了癌细胞对5-FU的敏感性，导致更多细胞死亡 [<xref ref-type="bibr" rid="hanspub.38186-ref25">25</xref>]。氯喹(CQ)作为实验性药物的自噬抑制剂，近年来相关研究发现其抗肿瘤作用，并在多种肿瘤中得以验证 [<xref ref-type="bibr" rid="hanspub.38186-ref26">26</xref>]。Cai等人通过体外实验对EC109食管鳞癌细胞进行了治疗发现CQ能够以时间和剂量依赖的方式抑制EC109细胞的增殖，同时也抑制了细胞的迁移能力。此外，CQ抑制了软琼脂上的菌落形成，也表明EC109细胞转化能力受损。为了证明实验过程中是否与自噬相关，通过检测氯喹处理过的细胞发现，自噬标志物明显降低。这也进一步表明自噬对于食管鳞癌的进展起到了促进作用 [<xref ref-type="bibr" rid="hanspub.38186-ref27">27</xref>]。</p></sec></sec><sec id="s8"><title>4. 自噬对于食管鳞癌治疗及预后</title><p>近年来针对自噬研究的深入，逐步发现自噬在肿瘤的发生、转移、治疗和耐药中起关键作用。调节自噬的靶向药物可能是抑制肿瘤进展和减少耐药的治疗方向。自噬能够参与多种免疫细胞的分化、发育和激活，从而在免疫中发挥重要作用。这也表明自噬可能是肿瘤免疫疗法的理想靶点。</p><sec id="s8_1"><title>4.1. 自噬对于食管鳞癌治疗的影响</title><p>鉴于自噬在肿瘤中的双重作用，目前针对药物的开发分为两大类：自噬促进剂及自噬抑制剂。已研究的自噬激活剂主要包括mTOR抑制剂、BH3模拟物、组蛋白脱乙酰基酶抑制剂和天然复合物等。Liu等人首次证明人参皂苷Rk3 (人参和三七中提取的生物活性成分)通过阻断PI3K/Akt/mTOR通路，通过激活细胞自噬抑制Eca109细胞的增殖。提示Rk3可能是一种自噬促进剂作为食管鳞癌抗肿瘤药物 [<xref ref-type="bibr" rid="hanspub.38186-ref28">28</xref>]。然而，相关研究却表现出了相反的结果，Zheng等人研究发现Rk3通过ESR2-NCF1-ROS途径抑制自噬体-溶酶体融合，通过CHEK1介导的DNA损伤检查点使食管鳞癌细胞对5-氟尿嘧啶诱导的细胞死亡敏感。目前越来越多的研究表面自噬对于肿瘤的进展有着明显的促进作用，因此对于自噬抑制剂的研究也相对多见，抑制肿瘤细胞自噬也成为抗肿瘤治疗的新思路。对于食管鳞癌治疗中，前文提到的CQ及其类似物羟氯喹(KCQ)通过抑制溶酶体的活性进而抑制自噬以此限制肿瘤细胞的增长。传统放疗对于食管鳞癌的治疗是一种重要手段，Chen等人通过对食管鳞癌细胞以2.5 Gy/min，总剂量6Gy的照射下，发现辐射可诱导自噬体的积累。应用3-MA (一种自噬全过程抑制剂)可有效抑制辐射诱导的自噬，通过进一步实验发现，抑制自噬在体内外均能显著提高肿瘤的放射敏感性。在EC9706细胞中，用10 mm 3-MA外加电离辐射处理细胞时，致敏增强比为1.76。此外，自噬抑制增加了肿瘤细胞的凋亡，降低了肿瘤细胞的增殖。在小鼠模型中，放疗和自噬抑制的联合作用导致了肿瘤体积和血管系统的显著减少。证实了辐射诱导的自噬对细胞死亡具有保护作用，抑制自噬可增强食管鳞癌的辐射敏感性 [<xref ref-type="bibr" rid="hanspub.38186-ref29">29</xref>]。Ma及Zheng等人研究发现高迁移率族蛋白1 (HMGB1)的表达与食管鳞癌的分期和存活之间的关系，进一步研究观察到HMGB1敲低的食管鳞癌细胞自噬水平降低，同时对辐射敏的感性升高。证明了高辐射敏感性可以通过诱导自噬来恢复。在食管鳞癌的临床样本中也证实了HMGB1与自噬的相关性以及与复发和预后的相关性。上述实验结果表明，高表达的HMGB1可能通过上调自噬来保护食管鳞癌细胞对于放疗的敏感性 [<xref ref-type="bibr" rid="hanspub.38186-ref30">30</xref>]。此实验通过敲除相关基因证明自噬对于放疗的敏感性，也恰巧排除了自噬抑制剂对于放疗的影响因素。</p></sec><sec id="s8_2"><title>4.2. 自噬增强是晚期食管鳞癌预后不良因素</title><p>自噬其对肿瘤的双重作用与食管鳞癌患者预后及生存期存在明显的相关性。相关研究发现晚期食管鳞癌患者与自噬存在明显负相关性。Jiang和Li等人通过标记自噬相关蛋白ULK1研究发现，食管鳞癌患者病理切片中ULK1的表达水平与患者总生存时间呈负相关(P &lt; 0.001)，说明ULK1表达水平越高，总存活时间越短。在所检测的标本中，ULK1低表达组的5年累计生存率为71.6%，而ULK1高表达组的5年累计生存率仅为43.8%。进一步实验发现，根据T分期进行分层生存分析，T1期T2期无显著差异，而ULK1的表达对T4期T3患者的总生存时间有差异(n = 185; log-rank, P = 0.001)，这表明T3-T4患者的生存期与之存在负相关(P = 0.045) [<xref ref-type="bibr" rid="hanspub.38186-ref31">31</xref>]。</p></sec></sec><sec id="s9"><title>5. 结语</title><p>随着对自噬研究的不断深入，发现自噬在食管鳞癌的发生、转移及治疗中都起到关键作用，一方面自噬通过消除氧化应激、维持基因组稳定而起到抑癌作用。另一方面，在形成恶性肿瘤时其可以在肿瘤微环境下促进食管鳞癌细胞的存活和增加化疗药物的耐药性。相关研究已经证实自噬抑制剂的应用在食管鳞癌化疗及放疗中都有着明显的作用。同时在肿瘤微环境中，自噬是免疫应答的重要调节因子，维持免疫细胞的稳态、激活和生物学功能。近年来肿瘤的免疫治疗研究众多，自噬与免疫系统之间存在着复杂的相互作用。研究发现自噬还可以通过B细胞，NKT和DC在肿瘤细胞和免疫反应性的细胞因子的释放中来增强免疫 [<xref ref-type="bibr" rid="hanspub.38186-ref32">32</xref>]。PD-L1/PD-1结合可导致附近T细胞因营养缺乏而发生自噬。自噬介导的免疫系统调控可能会增强或减弱免疫治疗的效果 [<xref ref-type="bibr" rid="hanspub.38186-ref33">33</xref>]。因此，在抗肿瘤免疫治疗中，我们应该尝试增强或抑制自噬，这也有望成为肿瘤免疫疗法的新途径。</p></sec><sec id="s10"><title>文章引用</title><p>张云龙,王振波. 自噬在食管鳞癌中的研究进展Research Progress of Autophagy in Esophageal Squamous Cell Carcinoma[J]. 临床医学进展, 2020, 10(10): 2323-2328. https://doi.org/10.12677/ACM.2020.1010350</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38186-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Domper Arnal, M.J., Ferrández Arenas, Á. and Lanas Arbeloa, Á. (2015) Esophageal Cancer: Risk Factors, Screening and Endoscopic Treatment in Western and Eastern Countries. World Journal of Gastroenterology, 21, 7933-7943. 
&lt;br&gt;https://doi.org/10.3748/wjg.v21.i26.7933</mixed-citation></ref><ref id="hanspub.38186-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Mizushima, N. and Komatsu, M. (2011) Autophagy: Renovation of Cells and Tissues. Cell, 147, 728-741. 
&lt;br&gt;https://doi.org/10.1016/j.cell.2011.10.026</mixed-citation></ref><ref id="hanspub.38186-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Dikic, I. and Elazar, Z. (2018) Mechanism and Medical Implications of Mammalian Autophagy. Nature Reviews Molecular Cell Biology, 19, 349-364. &lt;br&gt;https://doi.org/10.1038/s41580-018-0003-4</mixed-citation></ref><ref id="hanspub.38186-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Onorati, A.V., Dyczynski, M., Ojha, R. and Amaravadi, R.K. (2018) Targeting Autophagy in Cancer. Cancer, 124, 3307-3318. &lt;br&gt;https://doi.org/10.1002/cncr.31335</mixed-citation></ref><ref id="hanspub.38186-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Noda, N.N. and Inagaki, F. (2015) Mechanisms of Autophagy. Annual Review of Biophysics, 44, 101-122. 
&lt;br&gt;https://doi.org/10.1146/annurev-biophys-060414-034248</mixed-citation></ref><ref id="hanspub.38186-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Levine, B., Mizushima, N. and Virgin, H.W. (2011) Autophagy in Immunity and Inflammation. Nature, 469, 323-335.  
&lt;br&gt;https://doi.org/10.1038/nature09782</mixed-citation></ref><ref id="hanspub.38186-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Yorimitsu, T. and Klionsky, D.J. (2005) Autophagy: Molecular Machinery for Self-Eating. Cell Death &amp; Differentiation, 12, 1542-1552. &lt;br&gt;https://doi.org/10.1038/sj.cdd.4401765</mixed-citation></ref><ref id="hanspub.38186-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Nakatogawa, H., Suzuki, K., Kamada, Y. and Ohsumi, Y. (2009) Dynamics and Diversity in Autophagy Mechanisms: Lessons from Yeast. Nature Reviews Molecular Cell Biology, 10, 458-467. &lt;br&gt;https://doi.org/10.1038/nrm2708</mixed-citation></ref><ref id="hanspub.38186-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Kim, Y.C. and Guan, K.L. (2015) mTOR: A Pharmacologic Target for Autophagy Regulation. Journal of Clinical Investigation, 125, 25-32. &lt;br&gt;https://doi.org/10.1172/JCI73939</mixed-citation></ref><ref id="hanspub.38186-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Wallot-Hieke, N., Verma, N., Schlütermann, D., et al. (2018) Systematic Analysis of ATG13 Domain Requirements for Autophagy Induction. Autophagy, 14, 743-763. &lt;br&gt;https://doi.org/10.1080/15548627.2017.1387342</mixed-citation></ref><ref id="hanspub.38186-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Kamada, Y., Yoshino, K., Kondo, C., Kawamata, T., Oshiro, N., Yonezawa, K. and Ohsumi, Y. (2010) Tor Directly Controls the Atg1 Kinase Complex to Regulate Autophagy. Molecular and Cellular Biology, 30, 1049-1058. 
&lt;br&gt;https://doi.org/10.1128/MCB.01344-09</mixed-citation></ref><ref id="hanspub.38186-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Simonsen, A. and Tooze, S.A. (2009) Coordination of Membrane Events during Autophagy by Multiple Class III PI3-Kinase Complexes. Journal of Cell Biology, 186, 773-782. &lt;br&gt;https://doi.org/10.1083/jcb.200907014</mixed-citation></ref><ref id="hanspub.38186-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Funderburk, S.F., Wang, Q.J. and Yue, Z. (2010) The Beclin 1-VPS34 Complex—At the Crossroads of Autophagy and beyond. Trends in Cell Biology, 20, 355-362. &lt;br&gt;https://doi.org/10.1016/j.tcb.2010.03.002</mixed-citation></ref><ref id="hanspub.38186-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Guo, F., Liu, X.Y., Cai, H.B. and Le, W.D. (2018) Autophagy in Neurodegenerative Diseases: Pathogenesis and Therapy. Brain Pathology, 28, 3-13. &lt;br&gt;https://doi.org/10.1111/bpa.12545</mixed-citation></ref><ref id="hanspub.38186-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Tompkins, K.D. and Thorburn, A. (2019) Regulation of Apoptosis by Autophagy to Enhance Cancer Therapy. Yale Journal of Biology and Medicine, 92, 707-718.</mixed-citation></ref><ref id="hanspub.38186-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Hill, S.M., Wrobel, L. and Rubinsztein, D.C. (2019) Post-Translational Modifications of Beclin 1 Provide Multiple Strategies for Autophagy Regulation. Cell Death &amp; Differentiation, 26, 617-629. 
&lt;br&gt;https://doi.org/10.1038/s41418-018-0254-9</mixed-citation></ref><ref id="hanspub.38186-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Wu, N., Zhu, Y.F., Xu, X., et al. (2018) The Anti-Tumor Effects of Dual PI3K/Mtor Inhibitor BEZ235 and Histone Deacetylase Inhibitor Trichostatin A on Inducing Autophagy in Esophageal Squamous Cell Carcinoma. Cancer, 9, 987-997.  
&lt;br&gt;https://doi.org/10.7150/jca.22861</mixed-citation></ref><ref id="hanspub.38186-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Du, H.L., Che, J.M., Shi, M.M., Zhu, L.G., Hang, J.B., Chen, Z.Y. and Li, H.C. (2017) Beclin 1 Expression Is Associated with the Occurrence and Development of Esophageal Squamous Cell Carcinoma. Oncology Letters, 14, 6823-6828.  
&lt;br&gt;https://doi.org/10.3892/ol.2017.7015</mixed-citation></ref><ref id="hanspub.38186-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Mathew, R., Karp, C.M., Beaudoin, B., et al. (2009) Autophagy Suppresses Tumorigenesis through Elimination of P62. Cell, 137, 1062-1075. &lt;br&gt;https://doi.org/10.1016/j.cell.2009.03.048</mixed-citation></ref><ref id="hanspub.38186-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Xu, H.D. and Qin, Z.H. (2019) Beclin 1, Bcl-2 and Autophagy. Advances in Experimental Medicine and Biology, 1206, 109-126. &lt;br&gt;https://doi.org/10.1007/978-981-15-0602-4_5</mixed-citation></ref><ref id="hanspub.38186-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J., Gao, F., Xu, T., et al. (2018) miR-503 Suppresses the Proliferation and Metastasis of Esophageal Squamous Cell Carcinoma by Triggering Autophagy via PKA/Mtor Signaling. International Journal of Oncology, 52, 1427-1442.  
&lt;br&gt;https://doi.org/10.3892/ijo.2018.4320</mixed-citation></ref><ref id="hanspub.38186-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Rosengren, T., Larsen, L.J., Pedersen, L.B., et al. (2018) TSC1 and TSC2 Regulate Cilia Length and Canonical Hedgehog Signaling via Different Mechanisms. Cellular and Molecular Life Sciences, 75, 2663-2680. 
&lt;br&gt;https://doi.org/10.1007/s00018-018-2761-8</mixed-citation></ref><ref id="hanspub.38186-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Sharifi, M.N., Mowers, E.E., Drake, L.E., et al. (2016) Autophagy Promotes Focal Adhesion Disassembly and Cell Motility of Metastatic Tumor Cells through the Direct Interaction of Paxillin with LC3. Cell Reports, 15, 1660-1672. 
&lt;br&gt;https://doi.org/10.1016/j.celrep.2016.04.065</mixed-citation></ref><ref id="hanspub.38186-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J., Gao, F.X., Xu, T., et al. (2020) CLDN1 Induces Autophagy to Promote Proliferation and Metastasis of Esophageal Squamous Carcinoma through AMPK/STAT1/ULK1 Signaling. Journal of Cellular Physiology, 235, 2245-2259.  
&lt;br&gt;https://doi.org/10.1002/jcp.29133</mixed-citation></ref><ref id="hanspub.38186-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Feng, Y., Gao, Y.j., Wang, D.Y., Xu, Z.H., Sun, W.X. and Ren, P. (2018) Autophagy Inhibitor (LY294002) and 5-Fluorouracil (5-FU) Combination-Based Nanoliposome for Enhanced Efficacy against Esophageal Squamous Cell. Carcinoma. Nanoscale Research Letters, 13, Article No. 325. &lt;br&gt;https://doi.org/10.1186/s11671-018-2716-x</mixed-citation></ref><ref id="hanspub.38186-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Quan, Y.J., Lei, H.G., Wahafu, W., Liu, Y.X., Ping, H., Zhang X.D. (2019) Inhibition of Autophagy Enhances the Anticancer Effect of Enzalutamide on Bladder Cancer. Biomedicine &amp; Pharmacotherapy, 120, Article ID: 109490. 
&lt;br&gt;https://doi.org/10.1016/j.biopha.2019.109490</mixed-citation></ref><ref id="hanspub.38186-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Yue, D., Zhang, D., Shi, X., et al. (2020) Chloroquine Inhibits Stemness of Esophageal Squamous Cell Carcinoma Cells through Targeting CXCR4-STAT3 Pathway. Frontiers in Oncology, 10, 311. 
&lt;br&gt;https://doi.org/10.3389/fonc.2020.00311</mixed-citation></ref><ref id="hanspub.38186-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Zheng, K., Li, Y., Wang, S.X., et al. (2016) Inhibition of Autophagosome-Lysosome Fusion by Ginsenoside Ro via the ESR2-NCF1-ROS Pathway Sensitizes Esophageal Cancer Cells to 5-Fluorouracil-Induced Cell Death via the CHEK1-Mediated DNA Damage Checkpoint. Autophagy, 12, 1593-1613. 
&lt;br&gt;https://doi.org/10.1080/15548627.2016.1192751</mixed-citation></ref><ref id="hanspub.38186-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Chen, Y.S., Li, X.H., Guo, L.M., et al. (2015) Combining Radiation with Autophagy Inhibition Enhances Suppression of Tumor Growth and Angiogenesis in Esophageal Cancer. Molecular Medicine Reports, 12, 1645-1652. 
&lt;br&gt;https://doi.org/10.3892/mmr.2015.3623</mixed-citation></ref><ref id="hanspub.38186-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Ma, H.B., Zheng, S.Y., Zhang, X.Z., et al. (2019) High Mobility Group Box 1 Promotes Radioresistance in Esophageal Squamous Cell Carcinoma Cell Lines by Modulating Autophagy. Cell Death &amp; Disease, 10, Article No. 136.  
&lt;br&gt;https://doi.org/10.1038/s41419-019-1355-1</mixed-citation></ref><ref id="hanspub.38186-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, S., Li, Y., Zhu, Y.H., et al. (2011) Intensive Expression of UNC-51-Like Kinase 1 Is a Novel Biomarker of Poor Prognosis in Patients with Esophageal Squamous Cell Carcinoma. Cancer Science, 102, 1568-1575. 
&lt;br&gt;https://doi.org/10.1111/j.1349-7006.2011.01964.x</mixed-citation></ref><ref id="hanspub.38186-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Keller, C.W., Loi, M., Ewert, S., et al. (2017) The Autophagy Machinery Restrains iNKT Cell Activation through CD1D1 Internalization. Autophagy, 13, 1025-1036. &lt;br&gt;https://doi.org/10.1080/15548627.2017.1297907</mixed-citation></ref><ref id="hanspub.38186-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Robainas, M., Otano, R., Bueno, S. and Ait-Oudhia, S. (2017) Understanding the Role of PD-L1/PD1 Pathway Blockade and Autophagy in Cancer Therapy. OncoTargets and Therapy, 10, 1803-1807. 
&lt;br&gt;https://doi.org/10.2147/OTT.S132508</mixed-citation></ref></ref-list></back></article>